Dianthus Therapeutics DNTH Income Statement
| TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | TTM Q3 '24 | ||
|---|---|---|---|---|---|---|
| $3.08M-36.6% | $4.85M-25.6% | $6.52M+4.6% | $6.24M+16.2% | $5.37M+30.3% | ||
| $116.95M+6.3% | $110.01M+8.0% | $101.83M+15.8% | $87.9M+34.3% | $65.47M+36.7% | ||
| $31.23M+5.6% | $29.56M+10.8% | $26.69M+6.8% | $24.99M+9.6% | $22.8M-8.8% | ||
| $143.39M+6.4% | $134.77M+8.9% | $123.72M+14.5% | $108.1M+22.5% | $88.27M+21.1% | ||
| $143.39M+6.4% | $134.77M+8.9% | $123.72M+14.5% | $108.1M+22.5% | $88.27M+21.1% | ||
| -$140.31M-8.0% | -$129.92M-10.9% | -$117.2M-15.1% | -$101.86M-22.9% | -$82.9M-20.6% | ||
| -4,558.4%-1,882pp | -2,676.6%-880pp | -1,796.4%-163pp | -1,633.7%-88.8pp | -1,545%+125pp | ||
| $14.84M-5.0% | $15.63M-7.7% | $16.93M-2.5% | $17.37M+9.8% | $15.82M+27.6% | ||
| $13.96M-7.9% | $15.17M-7.9% | $16.47M-2.5% | $16.9M+6.8% | $15.81M+30.9% | ||
| -$126.35M-10.1% | -$114.75M-13.9% | -$100.73M-18.6% | -$84.97M-26.6% | -$67.09M-18.4% | ||
| -4,104.8%-1,741pp | -2,364.1%-820pp | -1,544%-181pp | -1,362.8%-112pp | -1,250.3%+126pp | ||
| -$3.49-7.1% | -$3.26-12.8% | -$2.89-10.7% | -$2.61— | —— | ||
| -$3.49-7.1% | -$3.26-12.8% | -$2.89-10.7% | -$2.61— | —— | ||
| 142.7M+2.6% | 139.2M+1.2% | 137.6M+7.9% | 127.4M+28.4% | 99.3M+44.0% | ||
| 142.7M+2.6% | 139.2M+1.2% | 137.6M+7.9% | 127.4M+28.4% | 99.3M+44.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$126.86M-10.7% | -$114.62M-14.1% | -$100.44M-18.3% | -$84.91M-27.9% | -$66.41M-17.1% | ||
| —— | —— | —— | —— | -$123K-35.2% | ||
| —— | —— | —— | —— | $685K+3,906% | ||
| -$947K-67.6% | -$565K-5.0% | -$538K+2.9% | -$554K-190% | -$191K+16.2% | ||
| -$140.31M-8.0% | -$129.92M-10.9% | -$117.2M-15.1% | -$101.86M-22.9% | -$82.9M-20.6% | ||
| -$140.2M-8.0% | -$129.81M-10.9% | -$117.1M-15.1% | -$101.77M-22.9% | -$82.81M-20.6% | ||
| -$140.2M-8.0% | -$129.81M-10.9% | -$117.1M-15.1% | -$101.77M-22.9% | -$82.81M-20.6% | ||
| -4,554.8%-1,881pp | -2,674.3%-879pp | -1,794.8%-163pp | -1,632.2%-88.9pp | -1,543.3%+124pp | ||
| -$140.31M-8.0% | -$129.92M-10.9% | -$117.2M-15.1% | -$101.86M-22.9% | -$82.9M-20.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dianthus Therapeutics's income statement data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.